Cancer Diagnostics Market – By Application, By Cancer Type, By End Use, Global Forecast, 2025 to 2034

Cancer Diagnostics Market Size

The global cancer diagnostics market size was valued at around USD 158.7 billion in 2024 and is estimated to grow at 9% CAGR from 2025 to 2034. Cancer diagnostics refers to the range of tests, procedures, and technologies used to detect and diagnose cancer at an early stage. The primary goal of cancer diagnostics is to identify the presence, type, location, and stage of cancer to guide appropriate treatment and improve patient outcomes.
 

The global cancer diagnostics market is significantly influenced by the alarming and persistent rise in cancer prevalence worldwide. According to the World Health Organization (WHO), approximately 20 million new cancer cases and 9.7 million cancer-related deaths were reported in 2022. Further, projections indicate that by 2050, the number of new cancer cases is expected to surpass 35 million, reflecting a staggering 77% increase from the 20 million cases recorded in 2022. This rising prevalence underscores the urgent need for early and accurate diagnostic methods, driving the demand for advanced cancer diagnostic technologies such as imaging, molecular diagnostics, among others, ultimately propelling market growth.
 

Furthermore, technological advancements in developing countries are significantly boosting the market. Increased investments in healthcare infrastructure and innovative technologies have led to the wider availability of advanced diagnostic tools. Techniques such as molecular diagnostics, imaging technologies, and telemedicine are facilitating earlier detection and more accurate diagnoses.
 

Cancer Diagnostics Market Trends

• Numerous initiatives by governments and health organizations to raise awareness about cancer and reduce the disease burden are expected to positively impact the growth of the market.
   
• One notable campaign launched by the Pan American Health Organization (PAHO), St. Jude Children's Research Hospital, and Childhood Cancer International aims to educate parents, caregivers, and healthcare professionals in Latin America and the Caribbean about the early warning signs of the most common cancers in children and adolescents.
   
• Additionally, February 15th is recognized as International Childhood Cancer Day to support children battling cancer. This observance seeks to enhance public awareness of prevalent pediatric cancers such as lymphoblastic leukemia, Hodgkin lymphoma, and retinoblastoma.
   

Cancer Diagnostics Market Analysis

Based on application, the market is divided into tumor biomarkers tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. The imaging segment is further bifurcated into ultrasound and radiology, mammography, MRI scan, PET scan, CT scan, SPECT, and other imaging. The imaging segment dominated the market accounting for 63.6% of revenue share in 2024.
 

• The segment is estimated to witness significant growth owing to the increasing adoption towards breast cancer screenings along with the rising number of awareness programs, leading to numerous women undergoing diagnosis for breast cancer.
   
• Introduction of technologically advanced products such as computer-aided images to detect cancer in dense breast tissue which will further boost the market size.
   

Based on cancer type, the cancer diagnostics market is bifurcated into bladder cancer, breast cancer, colon and rectal cancer, endometrial cancer, kidney cancer, leukemia, liver and lung cancer, melanoma, non-Hodgkin lymphoma, pancreatic cancer, prostate cancer, thyroid cancer, and other cancer types. The liver and lung cancer segment accounted for a 18.4% market share in 2024 and is projected for significant growth to reach USD 65.5 billion by 2034.
 

• Unhealthy dietary habits, increased smoking and alcohol consumption as well as other environmental factors are the major impact rendering factors in the market growth. Tobacco consumption is the key factor that has escalated the number of lung cancer cases across the globe.
   
• According to World Health Organization (WHO), consumption of tobacco is responsible for the death of approximately 7 million people each year, globally. Moreover, nearly 80% of the smokers live in low and middle-income countries.
   
• Furthermore, increasing prevalence of lung and liver cancer in emerging economies will further foster segmental growth. The liver-lung cancer segment will foresee significant growth over the projected period owing to the increasing prevalence of cancer across globe especially liver and lung cancer.
   
• Thus, the growing prevalence of liver-lung cancer among the population base will propel the demand for cancer diagnostics.
   

Based on end use, the cancer diagnostics market is bifurcated into hospitals, diagnostic laboratories, diagnostic imaging centers, and cancer research institutes.
 

• Hospitals segment held a significant revenue share in 2024 and is predicted to witness similar growth during the forecast period.
   
• High adoption rates for technologically advanced biopsy, mammography, and other devices utilized in treatment of cancer will increase the number of diagnoses carried out in hospital settings.
   
• Furthermore, availability of skilled professionals to operate advanced cancer diagnosis equipment as well as favorable reimbursement policies for various cancer diagnosis procedures performed in hospital settings will surge the segment revenue.
   

• The U.S. cancer diagnostics market is projected to grow significantly, reaching USD 135 billion by 2034.
   
• The incidence of cancer in the U.S. is on the rise due to several factors, including an aging population, lifestyle choices such as smoking and sedentary behavior, and environmental exposures.
   
• According to projections from the American Cancer Society, around 2,001,140 new cancer cases and 611,720 cancer-related deaths are expected in 2024, stimulating the demand for effective diagnostic tools.
   

The cancer diagnostics market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Innovative diagnostic technologies are transforming cancer care in the UK. The development and adoption of advanced methods, such as liquid biopsy, molecular diagnostics, and next-generation sequencing (NGS), are enhancing the ability to detect cancers earlier and with greater accuracy.
   
• These advancements enable healthcare providers to identify specific cancer types and their genetic mutations, which are essential for personalized treatment strategies.
   

Japan cancer diagnostics market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The trend toward personalized medicine is gaining momentum in Japan. As healthcare providers increasingly adopt treatment strategies tailored to individual patient profiles based on genetic and molecular information, the need for precise and reliable diagnostic tests will continue to rise. This focus on personalized approaches will be crucial in enhancing treatment outcomes for cancer patients.
   

The cancer diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Awareness of the importance of early cancer detection and screening is increasing among the Saudi population. Public health campaigns and initiatives, such as the Ministry of Health’s National Campaign for Breast Cancer Awareness, are actively educating people about cancer risks and the advantages of regular screenings.
   
• Therefore, as participation in these programs grows, the demand for cancer diagnostic services is anticipated to rise.
   

Cancer Diagnostics Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. A key strategy for participants is investing in the development of advanced diagnostic technologies, such as liquid biopsies, next-generation sequencing (NGS), and AI-driven imaging, to enhance accuracy and efficiency. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for non-invasive and cost-effective diagnostic solutions. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the cancer diagnostics industry include:

• Abbott Laboratories
• AB Sciex Pte
• Agilent Technologies
• Becton, Dickinson and Company
• Biocare Medical
• Biocartis
• Biomerieux
• Bio-Rad Laboratories
• Danaher Corporation
• F-Hoffmann-La Roche
• GE Healthcare
• Hologic
• Johnson & Johnson
• Koninklijke Philips
• Myriad Genetics
• QIAGEN
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
   

Cancer Diagnostics Industry News:

• In March 2023, QIAGEN N.V. formed a strategic partnership with the global pharmaceutical company Servier to develop a companion diagnostic test for TIBSOVO. Through this agreement, QIAGEN aimed to create a real-time in vitro PCR test for treating the blood cancer acute myeloid leukemia (AML). This partnership reinforced QIAGEN's position as a key player in oncology diagnostics and aligned with its strategy to innovate in precision medicine.
   
• In January 2023, Agilent entered into an agreement with Quest Diagnostics, enabling providers and patients across the U.S. to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This collaboration supported Agilent's business expansion and drove significant revenue growth.
   

The cancer diagnostics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Application

• Tumor biomarkers tests
• Imaging
  • Ultrasound and radiology
  • Mammography
  • MRI scan
  • PET scan
  • CT scan
  • SPECT and other imaging
• Biopsy
• Liquid biopsy
• Immunohistochemistry
• In situ hybridization

Market, By Cancer Type

• Bladder cancer
• Breast cancer
• Colon and rectal cancer
• Endometrial cancer
• Kidney cancer
• Leukemia
• Liver and lung cancer
• Melanoma
• Non-hodgkin lymphoma
• Pancreatic cancer
• Prostate cancer
• Thyroid cancer
• Other cancer types           

Market, By End use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes            

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE